RECOMMENDATIONS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ( MASH) DISEASE MANAGEMENT: A MODIFIED DELPHI PANEL

被引：0
|
作者：
Watzker, Anna [1 ]
Delegge, Mark [2 ]
Fernandes, Gail [1 ]
Melaragno, Matthew [1 ]
Williams, Rhys [2 ]
Godinho, Fatima [2 ]
Drymaliti, Kyriaki [2 ]
Engel, Samuel [1 ]
机构：
[1] Merck & Co Inc, Rahway, NJ USA
[2] IQVIA, Durham, NC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1730
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [32] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [33] Metabolic Dysfunction-Associated Steatohepatitis and Cardiovascular Disease Prevention: Is Resmetirom Useful?
    Borozan, Sanja
    Vujosevic, Snezana
    Mikhailidis, Dimitri P.
    Muzurovic, Emir
    CURRENT VASCULAR PHARMACOLOGY, 2025, 23 (01) : 4 - 7
  • [34] Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease
    Lurje, Isabella
    Tacke, Frank
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (06) : 1034 - 1037
  • [35] Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
    Maretti-Mira, Ana C.
    Salomon, Matthew P.
    Chopra, Shefali
    Yuan, Liyun
    Golden-Mason, Lucy
    BIOMEDICINES, 2024, 12 (05)
  • [36] IMPROVED DIAGNOSTIC ACCURACY OF VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY BASED TESTS IN IDENTIFYING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND AT-RISK MASH IN OBESE AND LEAN INDIVIDUALS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Quek, Joo Wei Ethan
    Tan, En Ying
    Lee, Shi Yan
    Huang, Daniel
    Lee, Jonathan
    Teng, Margaret
    Ng, Cheng Han
    Syn, Nicholas
    Wee, Aileen
    Soon, Shook Ting Gwyneth
    Jumat, Nur Halisah
    Dan, Yock Young
    Muthiah, Mark
    HEPATOLOGY, 2024, 80 : S620 - S621
  • [37] Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study
    Kumar, Jata Shankar
    Bhardwaz, Priyanshu
    Kar, Premashis
    JOURNAL OF HEPATOLOGY, 2024, 80 : S609 - S610
  • [38] MACHINE LEARNING MODELS FOR PREDICTING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE GENERAL UNITED STATES POPULATION
    Khalid, J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2024, 27 (06) : S268 - S268
  • [39] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [40] New and emerging treatments for metabolic dysfunction-associated steatohepatitis
    Tincopa, Monica A.
    Anstee, Quentin M.
    Loomba, Rohit
    CELL METABOLISM, 2024, 36 (05) : 912 - 926
12345